

Edgar Filing: NANOMETRICS INC - Form SC 13G/A

NANOMETRICS INC
Form SC 13G/A
January 23, 2007

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)
Information statement pursuant to Rules 13d-1 and 13d-2

Under the Securities Exchange Act of 1934
(Amendment No.1)

Nanometrics Incorporated
(Name of Issuer)

Common Stock
(Title of Class of Securities)

630077105
(CUSIP Number)

Date of Event Which Requires Filing of this Statement: December 31, 2006

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 630077105 13G

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Royce & Associates, LLC 52-2343049
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) []
(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,190,400
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,190,400
PERSON 8 SHARED DISPOSITIVE POWER
WITH
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON 1,190,400
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES []
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.59%
12 TYPE OF REPORTING PERSON
IA

Edgar Filing: NANOMETRICS INC - Form SC 13G/A

CUSIP No. 630077105 13G

Item 1(a) Name of Issuer:

Nanometrics Incorporated

Item 1(b) Address of Issuer's Principal Executive Offices:

Chief Financial Officer

1550 Buckeye Drive

Milpitas, CA 95035

Item 2(a) Name of Persons Filing:

Royce & Associates, LLC

Item 2(b) Address of Principal Business Office, or, if None, Residence:

1414 Avenue of the Americas, New York, NY 10019

Item 2(c) Citizenship:

New York Corporation

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

630077105

Item 3 If this statement is filed pursuant to rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

(a) Broker or Dealer registered under Section 15 of the Act

(b) Bank as defined in Section 3(a)(6) of the Act

(c) Insurance Company as defined in Section 3(a)(19) of the Act

(d) Investment Company registered under Section 8 of the Investment Company Act

(e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940

(f) Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund

(g) Parent Holding Company, in accordance with Rule 13d-1 (b) (ii) (G)

(h) Group

CUSIP No. 630077105 13G

Item 4 Ownership

(a) Amount Beneficially Owned:

1,190,400

(b) Percent of Class:

6.59%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote

1,190,400

(ii) shared power to vote or to direct the vote

(iii) sole power to dispose or to direct the disposition of

1,190,400

(iv) shared power to dispose or to direct the disposition of

Item 5 Ownership of Five Percent or Less of a Class.

Item 6 Ownership of More than Five Percent on Behalf of Another Person .

NOT APPLICABLE

Item 7 Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company.

NOT APPLICABLE

Item 8 Identification and Classification of Members of the Group.

NOT APPLICABLE

Item 9 Notice of Dissolution of Group.

NOT APPLICABLE

Edgar Filing: NANOMETRICS INC - Form SC 13G/A

CUSIP No. 630077105 13G
Item 10 Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to it is true, complete and correct.

Date: January 23, 2007

By: Daniel A. O'Byrne, Vice President

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 – Results of Operations and Financial Condition.

On March 30, 2012, Synthetic Biologics, Inc., a Nevada corporation (the “Registrant”), issued the attached press release that included financial information for its fiscal year ended December 31, 2011. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated March 30, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 30, 2012 SYNTHETIC BIOLOGICS, INC.
(Registrant)

By: /s/ C. Evan Ballantyne
Name: C. Evan Ballantyne
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Exhibits.

99.1 Press Release issued by Synthetic Biologics, Inc. dated March 30, 2012